NGNE241115C70000
- 4.50
- +1.50+50.00%
Neurogene Newsroom
Crude Oil Gains 3%; Constellation Energy Shares Tumble After Q3 Results
Neurogene Up Nearly 45%, on Pace for Largest Percent Increase Since December 2019 -- Data Talk
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday
12 Health Care Stocks Moving In Monday's Intraday Session
Neurogene Entered Securities Purchase Agreement For A PIPE Investment, Expected To Result In Gross Proceeds Of $200M
Neurogene Secures $200M for Genetic Therapy Development
Express News | Neurogene Inc - Proceeds Expected to Fund Company Into Second Half of 2027
Neurogene Announces Oversubscribed $200 Million Private Placement
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
BMO Capital analyst Keith Tapper CFA maintains $Neurogene(NGNE.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 80.0% and a
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook
Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401
Neurogene's NGN-401 Wins Key FDA Designation
Neurogene's NGN-401 Shows Promise for Rett Syndrome
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Neurogene Analyst Ratings
Buy Rating for Neurogene Based on Strong Clinical Prospects and Technological Advantages
Express News | Neurogene Inc : H.c. Wainwright Cuts Target Price to $49 From $51